

# Inside Aderis Pharmaceuticals



## Launch of Our Quarterly Shareholder's Newsletter

Welcome to the first issue of *Inside Aderis Pharmaceuticals*.

This quarterly newsletter is dedicated to providing our shareholders with timely information about what's happening and what's coming up.

We hope you'll find summaries of our news, conference presentations, interviews and events informative. We'll update you on advancements in the product pipeline and relevant web links to current research locations.



All shareholders and those interested in Aderis Pharmaceuticals are encouraged to register for email alerts through Aderis' Website Information Request Page.

*Inside Aderis Pharmaceuticals* will be available online at [www.aderis.com](http://www.aderis.com) in PDF format. If you prefer you may request a printed copy by calling 508-497-2300 ext. 233 or by email at [info@aderis.com](mailto:info@aderis.com).

## Aderis Pharmaceuticals Business Profile

Earlier this year we completed a Business Profile for BBC America and EuroNews broadcasts. We had expected to air these in March but the IPO "quiet period" precluded us from broadcasting. This "quiet period" actually extended through the end of August.

The program aired in the US on October 29, 2002 on BBC America and throughout Europe on EuroNews. It was broadcast simultaneously in English, French, German, Spanish and Italian to 93 million viewers in 43 countries.

The US program featured segments by Peter Savas, Aderis' CEO, Bill Fitzsimmons from Fujisawa, Matt Geller, from CIBC, James Garvey, from Schroder Ventures and Don McAfee PhD, Aderis' Founder and Chief Technical Officer.

We have a limited supply of broadcast DVDs available. If you would like one, please email [scorreia@aderis.com](mailto:scorreia@aderis.com) and include your name, full mailing address and phone number.

## Shareholder Update

Volume 1, Issue 1

December 2002

Fall/Winter Events

- *BioVenture*  
Oct. 1-2, 2002
- *BioContact*  
Oct. 2-4, 2002
- *UBS Warburg Global Life Sciences Conference*  
Oct. 7-11 2002
- *Parkinson's Study Group Symposium*  
Oct. 13, 2002
- *Virginia BioTechnology Association Conference*  
Oct. 14-16, 2002
- *Techvest Healthcare —North America*  
Oct. 22-23, 2002
- *SRI's Biofinancing Conference "The Business of Biotech"*  
Oct. 27-30, 2002
- *Mass Opportunities Investor Conference*  
Oct. 28-29, 2002
- *CIBC Healthcare Conference*  
Nov. 4-7, 2002
- *Int'l Congress of Parkinson's Disease and Movement Disorders*  
Nov. 10-14, 2002
- *American Heart Association Scientific Sessions*  
Nov. 17-20, 2002
- *MJFF's "A Funny Thing Happened on the Way to a Cure for Parkinson's"*  
Dec. 7, 2002

EuroNews

BBC AMERICA

# Active Fall/Winter 2002 Conference Schedule

Aderis' management and scientific staff attended investment, scientific and industry-focused conferences throughout 2002.

This fall our senior staff was invited to present at investor conferences such as CIBC Healthcare, UBS-Warburg Life Sciences Conference, BioVenture and TechVest.

Our business development team has met with technical and business contacts at scientific and partnering conferences where they are looking

for additional development opportunities.

We attended a plethora of CNS and cardiology meetings where clinical trial results from our partners and their investigators have been recognized during podium and poster presentations. We've also been able to keep our fingers on the pulse of the market.



Aderis' staff attended a blend of investment, scientific and industry-focused conferences.

# A Funny Thing Happened on the Way to Cure Parkinson's

Aderis Pharmaceuticals helped support The Michael J. Fox Foundation for Parkinson's Research's annual fund raising effort.



This year's event was held December 7th in New York City.

This gala evening of comedy and mu-

sic raised more than \$4.5 million, all of which is used to fund Parkinson's related research. This year the Foundation honored Muhammad Ali for his tireless dedication to raising awareness and funds. The hosts of the evening were Whoopi Goldberg and Drew Carey with appearances by Cameron Diaz, Leonardo DiCaprio, Heather Locklear and Martin Scorsese.



More than 1000 attended this gala event that honored Muhammad Ali. All proceeds will be used to fund Parkinson's research.



Aderis' CEO, Peter Savas, will be a featured guest on Delta Air Lines in-flight radio program "The Biotech Report" airing in January and February 2003. His interview highlights the development of rotigotine CDS in the treatment of Parkinson's disease.

Broadcast on a worldwide network of 35,000 flights, "The Biotech Report" will provide information on biotech

and the companies who are involved in the research and development of healthcare products.

We invite you to join 6.2 million other executive travelers including business leaders, corporate officers and frequent flyers

traveling on Delta Air Lines to listen to this report. If you're not planning to fly, our website will contain a link to the broadcast and it will also be available for 6 months at

[www.skyradionet.com](http://www.skyradionet.com).



Hear Peter Savas in January & February on the in-flight program "The Biotech Report"

## Clinical Trials Update – Rotigotine CDS, DTI-0009, Binodensin and MRE-0094

### Rotigotine CDS— Dopamine Agonist for Parkinson's Disease

There are three Phase III trials underway for rotigotine CDS in Parkinson's disease. In the US, an early stage trial is now fully enrolled and a late-stage patient trial is still enrolling. The 3-armed comparator European trial in early stage patients is also fully enrolled. Schwarz says results from these trials will be available in early 2004.

During the Movement Disorders meeting, three renowned PD investigators all agreed that continuous delivery of a dopamine agonist to the brain would be of real benefit to PD patients and provide multiple advantages in the reduction of symptoms and improved drug compliance. They point at a patch as a "very acceptable" treatment to doctors and patients.

### Rotigotine CDS — Low Dose Dopamine Agonist for Restless Legs Syndrome

Final analysis of data from a Phase IIa Proof of Concept trial were presented at the 7th International Congress of Parkinson's Disease and Movement Disorders held November 10-13<sup>th</sup> in Miami, Florida. The results indicate that the

*"Rotigotine CDS Patch—the future of Parkinson's disease therapy."*

— Schwarz Pharma AG

drug was well tolerated at all dose levels and induced a statistically significant reduction in symptoms. These trials were conducted in Europe. Phase IIb dosing trials are scheduled to begin in Spring 2003.

### DTI-0009 — Adenosine A<sub>1</sub> Agonist for Atrial Fibrillation

For the IV dosage form, three Phase IIb trials are underway that will enroll 220 patients and are designed to determine the dose range and heart rate response. At the American Heart Association 2002 Scientific Sessions November 17-20, the DTI-0009 study group presented evidence that DTI-0009 produced dose-dependent negative dromotropic effects which were rapid in onset and sustained for up to 20 minutes. No effects on blood pressure and no significant bradycardia were observed.



Three Phase III trials of rotigotine CDS for Parkinson's disease continue in Europe and the US. Phase IIb trials for Restless Legs Syndrome should begin in 2003.

### Binodensin (MRE-0470) — Adenosine A<sub>2A</sub> Agonist for Pharm Stress Cardiac Imaging

Late this summer MRE-0470 received its USAN approved name and is now referred to as binodensin. King Pharmaceuticals concluded fully-enrolled Phase IIb trials in August ending three months ahead of schedule. This trial was conducted at 30 sites and all patients received both adenosine and binodensin scans. The Phase III trials are due to begin in 2003.

### MRE-0094 — Adenosine A<sub>2A</sub> Agonist for Wound Healing in Diabetic Foot Ulcers

King Pharmaceuticals has initiated a Phase I/IIa trial with MRE 0094, an A<sub>2A</sub> agonist, administered as a topical gel in patients with diabetic foot ulcers. This initial trial is expected to conclude in 2003.



## Bio Business Review Exclusive Interview Featured in the UBS Warburg Health & Life Sciences Review Issue

An exclusive interview conducted with Peter Savas and Ken Rice for *CEO Talk* and for a special UBS Warburg Health & Life Sciences edition of the *BioBusiness Review* is now online at the Bio Business Networks website.

The November issue of BioBusiness Review provides a transcript of the interview. This publication is an investor research newsletter focusing specifi-

cally on life science industry financial news and corporate information.

The audio interview was conducted by Dr. Tan Khandaker M.D. Peter and Ken discussed Aderis' therapeutic focus, pipeline, core technologies, and partnerships. They also covered the market opportunities and the company's future prospects.

Visit the Events area of our website for

**CEO Talk**  
Khandaker M.D.

**BiObn**  
Bio Business Networks

a direct link to both the audio interview and a downloadable PDF file of the article. For more information about the BioBusiness Network, visit their website at <http://www.biobn.com>.

## Shareholder Update

Aderis Pharmaceuticals  
85 Main Street  
Hopkinton, MA 01748

Phone: 508-497-2300  
Fax: 508-497-9553  
Email: [info@aderis.com](mailto:info@aderis.com)

*We're on the  
web.  
Visit us at  
[www.aderis.com](http://www.aderis.com)*



## Parkinson's Disease Advocacy Aderis Pharmaceuticals and Schwarz Pharma support the Parkinson's Action Network (PAN) and the Morris Udall Awards

More than 300 Parkinson's Disease advocates gathered in May 2002 to attend a week of educational and congressional meetings during PAN's Annual Public Policy Forum.

Working closely with PAN we arranged for Dr. Joseph Bianchine of Schwarz Pharma to be one of three pharmaceutical industry speakers chosen to update the attendees about new treatment alternatives. Following his presentation, Dr. Bianchine fielded questions regarding "the Patch" from dozens of interested individuals. Schwarz reported that Phase III clinical trial enrollment increased following this meeting.

The week culminated in the Morris K. Udall Award Dinner attended by nearly 1,000 dignitaries. This year PAN honored US Senator Tom Harkins and US

Representative Jerry Lewis for their visionary leadership, public service and interest in the battle for a Parkinson's

cure. Aderis sponsored the VIP reception for this event. Sam Donaldson served as Master of Ceremonies with

US political analyst and author of *Saving Millie*, Morton Kondracke.

Michael J. Fox and the Udall family made numerous other award presentations including the first "Millicent Kondracke Award for Outstanding Advocacy."

The 2003 awards will be held on May 15<sup>th</sup> in Washington DC.

*See insert page for more pictures.*



*Aderis Pharmaceuticals founders, Don McAfee, Jim Peck and Gevork Minaskanian with Mort and Millie Kondracke at the Morris K. Udall Awards Dinner last May in Washington, DC.*

*Aderis Pharmaceuticals develops small molecule drug candidates that act selectively to either inhibit or increase the activity of certain proteins, such as receptors and enzymes, that regulate important physiologic functions.*

*We currently have four drug candidates in six clinical development programs. Our lead compound, rotigotine CDS, on a unique transdermal patch, will conclude Phase III trials for Parkinson's disease in 2003. A Phase II trial was recently completed utilizing a low-dosage rotigotine patch for Restless Legs Syndrome. Other product candidates are in development for cardiac diagnostic imaging, rate control in atrial fibrillation and wound healing in diabetic foot ulcers.*

*We have strategic alliances with Schwarz Pharma AG, Fujisawa Healthcare, and King Pharmaceuticals. Our corporate and research headquarters are in Hopkinton, Massachusetts and Richmond, Virginia respectively.*

Certain statements in this newsletter that are not historical fact constitute "forward-looking statement." Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company's development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for company's intellectual property or trade secrets and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors some but not all may have been mentioned above.



Sam Donaldson



Mark Udall



Don, Ken & Michael



Peter & Millie



Peter & Mort Kondracke



Joan Samuelson & Don



Peter & Michael



Joe Bianchine & the Patch



Peter & Rep. Jerry Lewis



Sen. Tom Harkin & Anne Udall



Wayne Roe